medigraphic.com
ISSN 1527-3172 (Digital)

2021, Número 2

<< Anterior Siguiente >>

MEDICC Review 2021; 23 (2)


Pretreatment HIV Drug-resistance Surveillance as a Tool for Monitoring: and Control of the HIV/AIDS Epidemic in Cuba

Machado-Zaldívar LY, Blanco-de Armas M, Dubed-Echevarría M, Díaz-Torres HM, López-Rizo LS, Pérez-Guevara MT, Lantero-Abreu MI, Rodríguez-Acosta M

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 64-68
Archivo PDF: 143.20 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tang MW, Shafer RW. HIV antiretroviral resistance.Scientifi c principles and clinical applications.Drug. 2012 Jun 18;72(9):e1–e25.

  2. Clutter DS, Jordan MR, Bertagnolio S, ShaferRW. HIV-1 drug resistance and resistance testing.Infect Genet Evol. 2016 Dec;46:292–307.

  3. World Health Organization. Surveillance of HIVdrug resistance in populations initiating antiretroviraltherapy (pre-treatment HIV drug resistance).Concept note. Geneva: World Health Organization;2014 Mar. 36 p. ISBN 978 92 4 1507 196.English, French.

  4. World Health Organization. Global action plan onHIV drug resistance 2017-2021. Geneva: WorldHealth Organization; 2017. p. 1–37.

  5. Ministry of Public Health (CU). Plan EstratégicoNacional para la Prevención y el Control de lasITS y el VIH/SIDA. 2014-2018. Havana: Ministryof Public Health (CU); 2015. ISBN: 978-959-283-115-5. Spanish.

  6. Ministry of Public Health (CU). Plan EstratégicoNacional para la prevención y el control de lasITS, el VIH y las hepatitis. 2019-2023. Havana:Ministry of Public Health (CU); 2019. ISBN: 978-959-283-180-3. Spanish.

  7. Rolo F, Miranda L, Wainberg MA, Gu Z, LobainaL, Noa E, et al. Envelope V3 Region Sequencesof Cuban HIV-1 Isolates. J Acquir Immune Defi cSyndr Hum Retrovirol. 1995 Jun 1;9(2):123–5.

  8. Cuevas MT, Ruibal I, Villahermosa ML, Díaz H,Delgado E, Vázquez-de Parga E, et al. HighHIV-1 genetic diversity in Cuba. AIDS. 2002 Aug16;16(12):1643–53.

  9. Blanco-de Armas M, Machado-Zaldívar LY, DíazH, Ruiz N, Romay-Franch D, Silva E. HIV-1genetic variability in Cuba and implications fortransmission and clinical progression. MEDICCRev. 2015 Oct;17(4):25–31.

  10. Ruibal-Brunet I, Cuevas MT, Díaz-Torres H, VillahermosaML, Noa-Romero E, Vázquez de PargaE, et al. Genotypic resistance mutations to antiretroviraldrugs in HIV-1 B and non-B subtypesfrom Cuba. Rev Panam Salud Pública. 2001Sep;10(3):174–80.

  11. Collazo Herrera M, Pérez Ávila J, TápanesPeraza R, Pérez Correa D, Martínez RodríguezA, Castro Peraza O, et al. Impacto económicosocialde la terapia antirretroviral de producciónnacional para el VIH/SIDA en Cuba. PharmacoeconSpan Res Artic. 2009;6:1–12. Spanish.

  12. Pérez L, Pérez Álvarez L, Carmona R, AragonésC, Delgado E, Thomson MM, et al. Genotypicresistance to antiretroviral drug in patientsinfected with several HIV type I genetic forms in Cuba. AIDS Res Hum Retroviruses. 2007Mar;23(3):407–14.

  13. Pérez L, Kourí V, Alemán Y, Abrahantes Y, CorreaC, Aragonés C, et al. Antiretroviral drug resistancein HIV-1 therapy-naive patients in Cuba.Infect Genet Evol. 2013 Jun;16:144–50.

  14. Alemán-Campos Y, Kourí-Cordellá V, Pérez-Santos L, Fonseca-Gómez C, Pérez-Ávila J,Ortega-González LM, et al. HIV-1 antiretroviralresistance in Cuba: 2009–2014. MEDICC Rev.2018 Jul;20(3):15–21.

  15. Machado LY, Dubed M, Díaz H, Ruiz N, RomayD, Valdés N, et al. Transmitted HIV type 1drug resistance in newly diagnosed Cubanpatients. AIDS Res Hum Retroviruses. 2013Feb;29(2):411–4.

  16. Machado LY, Díaz H, Blanco M, Dubed M, RuizN, Martínez L, et al. Emergence of the transmittedresistance of HIV-1 to antiretroviral drugs inCuban patients during the period 2009-2016.J Internat AIDS Soc. 2018 Apr 19;21(Suppl3):e25093.

  17. Machado LY, Blanco M, López LS, Díaz HM,Dubed M, Valdés N, et al. National survey of pretreatmentHIV drug resistance in Cuban patients.PLoS One [Internet]. 2019 Sep 3 [cited 2020 Sep26];14(9):e0221879. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719847/

  18. Lapadula G, Izzo I, Gargiulo F, Paraninfo G,Castelnuovo F, Quiros-Roldan E, et al. Updatedprevalence of genotypic resistance amongHIV-1 positive patients naïve to antiretroviraltherapy: a single center analysis. J Med Virol.2008;80(5):747–53.

  19. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Publications.Overview. Guidelines on the public healthresponse to pre-treatment HIV drug resistance; 2017 Jul 1 [cited 2020 Sep 26]. 84 p. Available at:https://www.who.int/publications/i/item/9789241550055

  20. World Health Organization. Update of recommendationson fi rst-and second line antiretroviralregimens 2019. Geneva: World Health Organization;2019 (WHO/CDS/HIV/19.15) License: CCBY-NC-SA 3.0. IGO.

  21. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Centro dePrensa. La OMS valida la eliminación de Cubade la transmisión de madre a hijo del VIH y dela sífi lis (comunicado de prensa); 2015 Jun 30[cited 2020 Sep 26]. Available at: http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/es/. Spanish.

  22. UNAIDS [Internet]. Geneva: UNAIDS;c2021. Nuestra Acción. 90-90-90: Tratamientopara todos; [cited 2020 Sep 26].Available at: https://www.onusida.org/es/resources/909090. Spanish.

  23. World Health Organization/HIVResNet DrugResistance Laboratory Strategy. Antivir Ther.2008 Apr;13 Suppl 2:49–57.

  24. World Health Organization. HIV drug resistancereport 2019. (WHO/CDS/HIV/19.21) License:CC BY-NC-SA 3.0. IGO. Geneva: World HealthOrganization; 2019.




2020     |     www.medigraphic.com